Comparing of toll like receptor 2 salivary level in head and neck radiotherapy patients with and without probiotic treatment
Phase 3
- Conditions
- Head And Neck Cancer.
- Registration Number
- IRCT20230624058564N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with head and neck cancer referred to the Imam Khomeini Hospital Cancer Institute who were diagnosed and operated on the basis of histopathology and are scheduled to undergo IMRT
Patients aged 18 years and older
Exclusion Criteria
1. Lack of written informed consent to participate in the study
2. Suffering from systemic diseases such as rheumatoid arthritis/hypertension/leukemia/systemic lupus erythromatous and other types of systemic diseases.
3.Having another malignancy and being treated for it
4. Patients who have already received chemotherapy or are undergoing chemotherapy.
5. Pregnant and lactating women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Toll like receptor 2. Timepoint: The expression level of Toll like receptor 2 is measured by ELISA method at two basic times (once before the start of treatment and once after the completion of radiotherapy treatment) and after the completion of radiotherapy treatment. Method of measurement: Toll like receptor 2 is performed through ELISA test kit and saliva test.
- Secondary Outcome Measures
Name Time Method The percentage of people who get grade 2 oral mucositis. Timepoint: They will be checked for oral mucositis once every three days, and the condition of oral mucositis will be recorded and if it is, its grade will be recorded. Method of measurement: Based on the amount of oral ulcers, it is examined and recorded by a specialist in oral and dental diseases.